Orchid Pharma - A Preferred Play On Import Substitution Opportunity: Systematix Initiates Coverage With A Buy

Initiate coverage on Orchid Pharma with a 'Buy' rating and a target price of Rs 884, based on 30 times FY26E earnings per share.

<div class="paragraphs"><p>Closeup of a hand holding capsules for photograph. (Source: freepik)</p></div>
Closeup of a hand holding capsules for photograph. (Source: freepik)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More